Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK

Journal of Pharmacological Sciences

Volumn 120, Issue 3, 2012, Pages 241-249

  Miyamoto, Chihiro ^a   Maehata, Yojiro ^a   Ozawa, Shigeyuki ^a   Ikoma, Takeharu ^a   Kubota, Eiro ^a   Izukuri, Kazuhito ^a   Kato, Yasumasa ^b   Hata, Ryu Ichiro ^a   Lee, Masaichi Chang Il ^a  

^a KANAGAWA DENTAL COLLEGE   (Japan)

^b OHU UNIVERSITY   (Japan)

Author keywords

5 (1,4 Diazepane 1 sulfonyl) isoquinoline; CXCL14 BRAK; Fasudil; Fibrosarcoma cell; Ras homologous small GTPase

Indexed keywords

CXCL14 CHEMOKINE; FASUDIL; MESSENGER RNA; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; FIBROSARCOMA; GENE EXPRESSION; MOUSE; NONHUMAN; SARCOMA CELL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 84869469250     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12177FP     Document Type: Article

References (47)

1. Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Christopherson K 2nd, Azam M, et al. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun. 1999;255:703-706. (Pubitemid 29294862)
2. Sleeman MA, Fraser JK, Murison JG, Kelly SL, Prestidge RL, Palmer DJ, et al. B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alpha-chemokine. Int Immunol. 2000;12:677-689. (Pubitemid 30248901)
3. Shurin GV, Ferris RL, Tourkova IL, Perez L, Lokshin A, Balkir L, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 2005;174:5490-5498. (Pubitemid 40593189)
4. Izukuri K, Suzuki K, Yajima N, Ozawa S, Ito S, Kubota E, et al. Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected]. Transgenic Res. 2010;19:1109-1117.
5. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Research. 2001;64:8262.
6. Starnes T, Rasila KK, Robertson MJ, Brahmi Z, Dahl R, Christopherson K, et al. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol. 2006;34:1101-1105. (Pubitemid 44080391)
7. Tessema M, Klinge DM, Yingling CM, Do K, Van Neste L, Belinsky SA. Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene. 2010;29:5159-5170.
8. Ozawa S, Kato Y, Komori R, Maehata Y, Kubota E, Hata R. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem Biophys Res Commun. 2006;348:406-412. (Pubitemid 44218985)
9. Ozawa S, Kato Y, Kubota E, Hata R. BRAK/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse. Biomed Res. 2009;30:315-318.
10. Ozawa S, Ito S, Kato Y, Kubota E, Hata R. Human p38 delta MAP kinase mediates UV irradiation induced up-regulation of the gene expression of chemokine BRAK/CXCL14. Biochem Biophys Res Commun. 2010;396:1060-1064.
11. Maehata Y, Ozawa S, Kobayashi K, Kato Y, Yoshino F, Miyamoto C, et al. Reactive oxygen species (ROS) reduce the expression of BRAK/CXCL14 in human head and neck squamous cell carcinoma cells. Free Radic Res. 2010;44:913-924.
12. Nishimura Y, Itoh K, Yoshioka K, Tokuda K, Himeno M. Overexpression of ROCK in human breast cancer cells: evidence that ROCK activity mediates intracellular membrane traffic of lysosomes. Pathol Oncol Res. 2003;9:83-95. (Pubitemid 36958628)
13. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995;270:29051-29054.
14. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med. 1999;5:221-225. (Pubitemid 29068531)
15. Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett. 2001;165:1-10. (Pubitemid 32206651)
16. Park JJ, Loh YP. How peptide hormone vesicles are transported to the secretion site for exocytosis. Mol Endocrinol. 2008;22:2583-2595.
17. Deng L, Li G, Li R, Liu Q, He Q, Zhang J. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol Ther. 2010;9:875-884.
18. Ho TJ, Huang CC, Huang CY, Lin WT. Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats. Eur J Appl Physiol. 2011;23:1037-1045.
19. Yang X, Di J, Zhang Y, Zhang S, Lu J, Liu J, et al. The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed Pharmacother. 2012;66:221-227.
20. Ohta T, Takahashi T, Shibuya T, Amita M, Henmi N, Takahashi K, et al. Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells. Cancer Biol Ther. 2012;13:25-33.
21. Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate. 2005;64:67-74. (Pubitemid 40734740)
22. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol. 1995;15:6443.
23. Sleeman MA, Fraser JK, Murison JG, Kelly SL, Prestidge RL, Palmer DJ, et al. B cell-and monocyte-activating chemokine (BMAC), a novel non-ELR alpha-chemokine. Int Immunol. 2000;12:677-689. (Pubitemid 30248901)
24. Ren XD, Kiosses WB, Schwartz MA. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J. 1999;18:578-585. (Pubitemid 29057242)
25. Pandey D, Goyal P, Siess W. Lysophosphatidic acid stimulation of platelets rapidly induces Ca2+-dependent dephosphorylation of cofilin that is independent of dense granule secretion and aggregation. Blood Cells Mol Dis. 2007;38:269-279. (Pubitemid 46518177)
26. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-532.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
28. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer. 2002;2:210-219. (Pubitemid 37328790)
29. Akhurst RJ. TGF-beta antagonists: why suppress a tumor suppressor? J Clin Invest. 2002;109:1533-1536. (Pubitemid 34663514)
30. Benatti P, Basile V, Merico D, Fantoni LI, Tagliafico E, Imbriano C. A balance between NF-Y and p53 governs the pro- and anti-apoptotic transcriptional response. Nucleic Acids Res. 2008; 36:1415-1428. (Pubitemid 351426096)
31. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20:242-248.
32. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009;28:65-76.
33. Berthold J, Schenkova K, Rivero F. Rho GTPases of the RhoBTB subfamily and tumorigenesis. Acta Pharmacol Sin. 2008;29:285-295. (Pubitemid 351316996)
34. Montani L, Bausch-Fluck D, Domingues AF, Wollscheid B, Relvas JB. Identification of new interacting partners for atypical Rho GTPases: a SILAC-based approach. Methods Mol Biol. 2012;827:305-317.
35. McKinnon CM, Lygoe KA, Skelton L, Mitter R, Mellor H. The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cells. Oncogene. 2008;27:6856-6865.
36. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002;2:133-142.
37. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3:582-591. (Pubitemid 37328830)
38. Liu S, Murph M, Panupinthu N, Mills GB. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle. 2009;8:3695-3701.
39. Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science. 1999;285:895-898. (Pubitemid 29381991)
40. Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S, Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem. 2000;275:3577-3582. (Pubitemid 30083067)
41. Nishimura Y, Yoshioka K, Bernard O, Himeno M, Itoh K. LIM kinase 1: evidence for a role in the regulation of intracellular vesicle trafficking of lysosomes and endosomes in human breast cancer cells. Eur J Cell Biol. 2004;83:369-380. (Pubitemid 39307174)
42. Fath KR, Trimbur GM, Burgess DR. Molecular motors are differentially distributed on Golgi membranes from polarized epithelial cells. J Cell Biol. 1994;126:661-675. (Pubitemid 24241380)
43. Hasson T, Mooseker MS. Molecular motors, membrane movements and physiology: emerging roles for myosins. Curr Opin Cell Biol. 1995;7:587-594.
44. Langford GM. Actin- and microtubule-dependent organelle motors: interrelationships between the two motility systems. Curr Opin Cell Biol. 1995;7:82-88.
45. Bi GQ, Morris RL, Liao G, Alderton JM, Scholey JM, Steinhardt RA. Kinesin- and myosin-driven steps of vesicle recruitment for Ca2+-regulated exocytosis. J Cell Biol. 1997;138:999-1008. (Pubitemid 27386451)
46. Izukuri K, Ito S, Nozaki N, Yajima N, Iwamiya M, Kawahara S, et al. Determination of serum BRAK/CXCL14 levels in healthy volunteers. Lab Medicine. 2010;41:478-482.
47. Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, Takakura K. A post-marketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol. 2007;68:126-131. (Pubitemid 47087900)